IAVI and its partners are advancing a diverse porfolio of select preventive HIV vaccine candidates.
IAVI details its organizational strategic vision for the period 2011-2015 made.
Engage with IAVI on your social media networks.
Study Summary:
This is an open-label study with an MVA vector-based HIV-1 clade A candidate vaccine, MVA.HIVA, in HIV-uninfected healthy male and female volunteers at low risk of HIV infection. On Day 0 and Day 21 study participants will receive a single intradermal injection of 5x10^7 pfu in 0.1ml in the latero-dorsal aspect over the deltoid muscle.